STR recently received final approval for the generic version of Sustiva (Efavirenz) 600mg tablet, which hasa market size of ~USD115m. The only other company having final approval for this product is Mylan - it had received final approval in February 2016 (with 180-day exclusivity post approval) and the product was launched on 1 February 2018. Final approval and subsequent launch by STR implies that the delay in launch by Mylan has forfeited its exclusivity. 4-5 other companies have also filed for this product. Considering the competitive dynamics (currently only a two-player market for the product), we expect STR to garner USD7-8m from this product on an annualized basis. In our view, this is an interesting opportunity, given the low base of US sales for STR.